These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 27919366

  • 1. LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response.
    Lappegård KT, Enebakk T, Thunhaug H, Ludviksen JK, Mollnes TE, Hovland A.
    J Clin Lipidol; 2016; 10(6):1481-1487. PubMed ID: 27919366
    [Abstract] [Full Text] [Related]

  • 2. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT, Enebakk T, Thunhaug H, Hovland A.
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [Abstract] [Full Text] [Related]

  • 3. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA.
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [Abstract] [Full Text] [Related]

  • 4. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA, Nohara A, Higashikata T, Tada H, Nakanishi C, Okada H, Konno T, Sakata K, Hayashi K, Inazu A, Mabuchi H, Yamagishi M.
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
    Lappegård KT, Kjellmo CA, Ljunggren S, Cederbrant K, Marcusson-Ståhl M, Mathisen M, Karlsson H, Hovland A.
    Transfus Apher Sci; 2018 Feb; 57(1):91-96. PubMed ID: 29398508
    [Abstract] [Full Text] [Related]

  • 6. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T.
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [Abstract] [Full Text] [Related]

  • 7. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, Žák P.
    Vnitr Lek; 2018 Sep; 64(1):43-50. PubMed ID: 29498875
    [Abstract] [Full Text] [Related]

  • 8. Different inflammatory responses induced by three LDL-lowering apheresis columns.
    Hovland A, Hardersen R, Sexton J, Mollnes TE, Lappegård KT.
    J Clin Apher; 2009 Sep; 24(6):247-53. PubMed ID: 19927364
    [Abstract] [Full Text] [Related]

  • 9. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
    Zenti MG, Stefanutti C, Sanga V, Altomari A, Fabris A, Dauriz M, Bonora E.
    J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, TESLA Investigators.
    Lancet; 2015 Jan 24; 385(9965):341-50. PubMed ID: 25282520
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01).
    Torres E, Goicoechea M, Hernández A, Rodríguez Ferrero ML, García A, Macías N, Anaya F.
    J Clin Apher; 2020 Jan 24; 35(1):9-17. PubMed ID: 31663632
    [Abstract] [Full Text] [Related]

  • 12. Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.
    Tanaka A, Inaguma D, Watanabe Y, Ito E, Kamegai N, Shimogushi H, Shinjo H, Koike K, Otsuka Y, Takeda A.
    Intern Med; 2017 Jan 24; 56(12):1531-1535. PubMed ID: 28626179
    [Abstract] [Full Text] [Related]

  • 13. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov 24; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
    Baum SJ, Sampietro T, Datta D, Moriarty PM, Knusel B, Schneider J, Somaratne R, Kurtz C, Hohenstein B.
    J Clin Lipidol; 2019 Nov 24; 13(6):901-909.e3. PubMed ID: 31759938
    [Abstract] [Full Text] [Related]

  • 16. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan 24; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 17. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M.
    Atherosclerosis; 2017 Jan 24; 256():134-145. PubMed ID: 27993383
    [Abstract] [Full Text] [Related]

  • 18. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D, RUTHERFORD-2 Investigators.
    Lancet; 2015 Jan 24; 385(9965):331-40. PubMed ID: 25282519
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
    Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H, MENDEL-2 Investigators.
    J Am Coll Cardiol; 2014 Jun 17; 63(23):2531-2540. PubMed ID: 24691094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.